SBUR Fall Symposium (2017)

November 9, 2017 to November 12, 2017

The development of epigenetic screens in combination with genetics represents a new frontier in personalized medicine that is required for effective decision making with respect to when and how to screen, treat, and counsel patients. However, many challenges remain before this concept can be fully implemented. Understanding the myriad of mechanisms associated with epigenetics, connecting the underlying genetic landscapes with epigenetic states, defining the context in which they occur in both normal and disease tissue, and determining whether epigenetics can provide opportunities for therapeutic intervention all still need to be resolved. A further requirement is the integration of multiple fields including medicine, basic and clinical medical research, genetics and genomics, biotechnology, data analysis and disease modeling. Decision making in personalized medicine is continually changing and advancing, and a concerted educational effort must be made to enable researchers and urologists to keep up with these changes. To keep up, researchers need (1) education on the components underlying genomic medicine and how these could be integrated to develop more effective, evidence-based approaches to patient care, (2) education regarding the different levels of complexity in a patient that would need to be considered in guiding precision medicine, including proteins, cell types, organs, and even organisms that live within the urologic tract and could influence treatment outcomes, and (3) education regarding the requirement of an multidisciplinary team approach across a wide range of disciplines to advance personalized medicine. 

Target Audience

  • Non-Urologist MD
  • Research/Scientist
  • Resident
  • Urologist

Learning Objectives

At the conclusion of this conference, the attendees should be able to:

  1. Highlight recent advances in genetic and epigenetic data in normal and urologic disease states
  2. Discuss the pros and cons of new technology to measure genetic and epigenetic changes
  3. Describe how the combined use of genetic and epigenetic data can affect patient care
  4. Identify collaborators across multiple disciplines to apply genetic and epigenetic data in patient care
     
Course summary
Available credit: 
  • 20.50 AMA PRA Category 1 Credit™
  • 20.50 Non-Physician Participation
Course opens: 
11/09/2017
Course expires: 
11/12/2020
Event starts: 
11/09/2017 - 12:00am EST
Event ends: 
11/12/2017 - 11:59pm EST
Add to calendar: 
Rating: 
0

PDF icon SBUR Fall 2017 Program.pdf

Tampa, FL
United States

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Urological Association (AUA) and the Society of Basic Urologic Research (SBUR). The AUA is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 20.50 AMA PRA Category 1 Credit™
  • 20.50 Non-Physician Participation
Please login or register to take this course.